- Cancer Biology & Biomarkers
- Chromatography & Mass Spectrometry
- Contract Research, Clinical Trials and Outsourcing
- Drug Discovery
- Drug Targets
- Flow Cytometry
- Informatics & Lab Automation
- Ingredients, Excipients and Dosages
- Microbiology & RMMs
- NIR, PAT & QbD
- Raman Spectroscopy
- Screening, Assays & High-Content Analysis
- Thermal Processing
- Events & Workshops
Global peripheral artery disease treatment market to peak in 2020
19 October 2015 • Author: Victoria White
The global treatment market for peripheral artery disease will expand in value from approximately $543.4 million in 2014 to a peak of $983.6 million in 2020, before falling to $816.3 million by 2024 due to the generic erosion of Brilinta and Xarelto, according to research and consulting firm GlobalData.
The Company’s latest report, PharmaPoint: Peripheral Artery Disease — Global Drug Forecast and Market Analysis to 2024, states that the initial dramatic increase in the value of the overall global PAD therapeutics space, which covers the eight major markets (8MM) of the US, France, Germany, Italy, Spain, UK, Japan, and urban China, will be partly attributable to the launch of several highly promising PAD drugs currently in late-stage pipeline development.
Shaan Thakerar, MSc, GlobalData’s Senior Analyst covering Cardiovascular and Metabolic Disorders, says three novel antithrombotic pharmacological agents, namely Merck & Co.’s Zontivity (vorapaxar), AstraZeneca’s Brilinta (ticagrelor), and Bayer and Janssen’s Xarelto (rivaroxaban), all have the capacity to reform the antiplatelet and anticoagulatory peripheral artery disease treatment landscape.
Thakerar comments, “The antithrombotic agents Xarelto, Zontivity, and Brilinta will bring new drug targets and novel mechanisms of action to the arsenal of long-term blood-thinning treatment strategies.
“The unveiling of Xarelto into the anticoagulant therapeutics space for PAD will mark the biggest step forward in the anticoagulant market since warfarin, but will come without the liabilities of its first-generation predecessor.”
The analyst adds that Brilinta, a first-in-class nonthienopyridine, will eventually displace clopidogrel, a second-generation thienopyridine, in the peripheral artery disease treatment paradigm by 2024.
Peripheral artery disease market predicted to become increasingly genericized
However, while the antithrombotic space is brimming with competition, GlobalData anticipates that the global antiplatelet and anticoagulant markets in peripheral artery disease will become increasingly genericized, progressively more saturated, and challenging to penetrate.
Thakerar continues: “Current pipeline agents, such as Brilinta and Xarelto, will eventually lose market exclusivity and patent protection, and these drugs will ultimately relinquish their stake in the peripheral artery disease marketplace to cheaper, generic copycats in most of the 8MM.
“During the forecast period, growth in the peripheral artery disease therapy market will also be hindered by the existence of cheap and established generic drugs, including aspirin, clopidogrel, and warfarin, as well as limited physician uptake of Brilinta, Zontivity, and Xarelto due to the heightened risk of bleeding associated with these treatments.”
ABB Analytical Measurement ACD/Labs ADInstruments Ltd Advanced Analytical Technologies GmbH Analytik Jena AG Astell Scientific Ltd Bachem AG Bibby Scientific Limited Bio-Rad Laboratories BioNavis Ltd Biopharma Group Black Swan Analysis Limited Charles Ischi AG | Kraemer Elektronik Cherwell Laboratories CI Precision Cobalt Light Systems Coulter Partners CPC Biotech srl Dassault Systèmes BIOVIA DiscoverX Edinburgh Instruments Enterprise System Partners (ESP) EUROGENTEC F.P.S. Food and Pharma Systems Srl IDBS JEOL Europe L.B. Bohle Maschinen + Verfahren GmbH Lab M Ltd. LabWare Linkam Scientific Instruments Limited Molins Technologies Multicore Dynamics Ltd Nanosurf New England Biolabs, Inc. Panasonic Biomedical Sales Europe B.V. PerkinElmer Inc ReAgent Russell Finex Limited Source BioScience Takara Clontech Tornado Spectral Systems Tuttnauer Watson-Marlow Fluid Technology Group Wickham Laboratories Limited Xylem Analytics YMC Europe GmbH Yusen Logistics